La cadena de opciones muestra datos clave de las opciones de acciones de ImmunityBio a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para ImmunityBio..

ImmunityBio (NASDAQ:IBRX) Bolsa, Cadena de Opciones

IMMUNITYBIO INC

ImmunityBio

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

IBRX

PGNY

Explora las acciones de salud más sobrevendidas según el RSI. Descubre cuáles podrían ser grandes oportunidades de inversión en el mercado.

3 acciones de salud infravaloradas: Oportunidades para inversores astutos

ImmunityBio Inc

Press Releases

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

Opinion

As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry

UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Small Cap

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

ImmunityBio Announces Houston's Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy

ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID

ANIX

CLDI

CRSP

CTMX

IOVA

ONCY

REGN

TSX:ONC

VRTX

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Alvotech

Apogee Therapeutics

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Cidara Therapeutics

Celcuity

CG Oncology

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Cogent Biosciences

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Denali Therapeutics

Dyne Therapeutics

Amicus Therapeutics

Galapagos NV - American Depositary Shares

Galapagos

IDEAYA Biosciences

Disc Medicine

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Mesoblast Limited - American Depositary Shares

Mesoblast

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Veracyte

D. Boral Capital

HC Wainwright & Co.

Piper Sandler

BTIG

Comments

ImmunityBio

ImmunityBio (IBRX) Opciones

ImmunityBio (NASDAQ:IBRX) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL